Are there any safety or efficacy data regarding the use of EGFR inhibitors in patients on hemodialysis for ESRD?

It's limited. Erlotinib is metabolized in the liver and pharmacokinetic data in patients on hemodialysis is similar to those with normal function. This was reported in a 3 patient case series (Togashi et al, JTO 2010). Appears comparable with osimertinib as well. A case report (Tamura et al, Lung Ca...